Hoth Therapeutics Inc., of New York, which is developing targeted therapeutics for patients suffering from indications such as atopic dermatitis, closed its IPO of 1.25 million shares at $5.60 each, resulting in gross proceeds of $7 million. In addition, the company has granted the underwriters a 30-day option to purchase up to an additional 187,500 shares at the IPO.